De-escalation Strategies in Human Papilloma Virus-Positive Oropharyngeal Cancer

Abstract

Human papilloma virus (HPV) is now attributable to most of the oropharyngeal squamous cell cancers (OPSCCs) occurring in western world. The HPV-associated OPSCC effect younger, otherwise healthy population and is typically associated with better outcome. Traditional treatment strategies, while successful, are associated with significant long-term morbidity and poorer quality of life. This has led to various trials and investigations to de-escalate the treatment in this patient population while maintaining excellent outcome. The objective of this review is to discuss various de-escalation strategies and trials.